First Cohort Dosed in Nyrada’s Phase I Clinical Trial

Highlights:
•First cohort of participants dosed in Nyrada’s Phase I first-in-human clinical trial.
•Six participants received NYR-BI03 while two participants received placebo.
•Phase I trial designed to assess safety, tolerability and pharmacokinetics of NYR-BI03.